---
anonymous_label: OUT-12
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 4ebebd81cc53a483833c6f2e53454256e0b42f26825fc6390dda6577d8c221aa
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-12

**Recommendation:** Run the Claim File Review.

**Why:** The current "success" is an illusion created by lagging indicators (renewals driven by temporary pricing) and misleading usage metrics (managers rerunning samples rather than adjusters using the tool in live production). You have a critical "black box" problem: you know adjusters are abandoning the tool (especially in health-liability) and that managers are using it for enablement rather than operations, but you don't know *why* the suggestions are being overridden or deemed unexplainable. The Claim File Review is the only option that provides qualitative, ground-truth evidence of whether DraftPath actually solves a problem or is simply being "bought" by executives and ignored by users.

**Strongest Reason Against:** This is the slowest, most manual method of validation. Unlike the Usage Quality Sprint (which uses automated analytics) or the Commercial Cleanroom (which tests price elasticity), a file review requires human labor and time. By the time you have a statistically significant sample of reviewed files, you may have already missed the window to pivot the product before the next major churn cycle.

**Observable Evidence to Change My Mind:** If the "wrong recommendation" tickets in the training channel spike significantly in volume and specificity (e.g., a clear pattern of "the tool consistently fails at X step"), the Usage Quality Sprint becomes more valuable because the problem has shifted from "hidden abandonment" to "vocal dissatisfaction," which is easier to track via event logs and tags.
